TCM
ANTX icon

TCG Crossover Management’s AN2 Therapeutics ANTX Stock Holding History

TCG Crossover Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,555,118
Closed -$1.66M – 39
2024
Q3 		$1.66M Hold
1,555,118
– – 0.14% 34
2024
Q2 		$3.34M Hold
1,555,118
– – 0.35% 29
2024
Q1 		$5.05M Sell
1,555,118
-1,123,091
-42% -$12.2M 0.4% 29
2023
Q4 		$54.9M Hold
2,678,209
– – 6.09% 4
2023
Q3 		$43.1M Buy
2,678,209
+1,388,889
+108% +$15.7M 6.34% 4
2023
Q2 		$11M Buy
+1,289,320
New +$9.27M 1.8% 16

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return

TCG Crossover Management's ANTX Position: Q4 2024 in Review

TCG Crossover Management sold out of AN2 Therapeutics (ANTX) in Q4 2024, closing a stake of 1,555,118 shares — an estimated $1.66M sold.

TCG Crossover Management first reported a position in ANTX in Q2 2023 and held it in 6 quarters. The position peaked at $54.9M in Q4 2023. 37 funds tracked by Wall St. Rank hold ANTX as of Q4 2024.

  • TCG Crossover Management reported no remaining AN2 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • TCG Crossover Management sold 1,555,118 AN2 Therapeutics shares in Q4 2024, an estimated $1.66M.
  • TCG Crossover Management first reported a position in AN2 Therapeutics in Q2 2023 and held it in 6 quarters.
  • TCG Crossover Management's AN2 Therapeutics position peaked at $54.9M in Q4 2023.
  • 37 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q4 2024.

Based on TCG Crossover Management's 13F filing for Q4 2024, filed 14 Feb 2025.